Skip to content

Evaluation of the effect of TauroLock™ and piperacillin-tazobactam in secondary prophylaxis of Port-Catheter infection.

Comparative clinical study of the effectiveness of TauroLock™ solution with piperacillin-tazobactam as secondary prophylaxis of Port-Catheter infection in children with cancer

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180309039013N1
Enrollment
50
Registered
2018-06-08
Start date
2018-03-21
Completion date
Unknown
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection due to port catheter. Infection and inflammatory reaction due to other internal prosthetic devices, implants and grafts

Interventions

Intervention 1: Intervention group: Individuals in this group will be injected from the antibiotic solution of Piperacillin Tazobactam in proportion to the port volume, 3-5 cc. Intervention 2: Control

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Days to 19 Years

Inclusion criteria

Inclusion criteria: Having Port-Catheter Age between 0-19 Having cancer

Exclusion criteria

Exclusion criteria: Critically ill patients Patients with severe coagulation problems No permission from child's parents

Design outcomes

Primary

MeasureTime frame
The rate of infection of systemic bloodstream incidence due to port infection. Timepoint: Before the beginning of the intervention, once a day during the intervention, and at the end of the intervention. Method of measurement: Positive blood culture according to standard microbiological process.

Secondary

MeasureTime frame
Port survival rate (No need to exit port or reload). Timepoint: Once a day during the intervention, and at the end of the intervention. Method of measurement: I will record the change of port by observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Amanati

Shiraz University of Medical Sciences

Ali_amanati_1356@yahoo.com+98 71 3632 3731

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026